Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches

Catherine Handy Marshall; Emmanuel S. Antonarakis

doi:10.1016/j.ctarc.2020.100164

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches

Catherine Handy Marshall, Emmanuel S. Antonarakis

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Immunotherapy, particularly immune checkpoint blockers, PARP inhibitors, and PSMA-targeted therapies are all increasingly being studied for the treatment of mCRPC although none are currently FDA-approved specifically for prostate cancer. Together these three classes of treatments may drastically change the future landscape of mCRPC. This review will cover what is currently known about the utility of these agents for the treatment of mCRPC, the areas of active research, and how these agents may be useful for patients in the future. It will also emphasize the notion of biomarker selection to help inform which patients are more likely to respond to these therapies.

Original language	English (US)
Article number	100164
Journal	Cancer Treatment and Research Communications
Volume	23
DOIs	https://doi.org/10.1016/j.ctarc.2020.100164
State	Published - 2020
Externally published	Yes

Bibliographical note

Funding Information:
Disclosures: CHM has received research funding to her institution from the Conquer Cancer Foundation (Bristol Myers Squibb) and travel support from Dava Oncology. She also serves as a paid consultant to McGraw-Hill publishing company. ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck. He has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol-Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Funding: This work was partially supported by National Institute of Health Cancer Center Support Grant P30CA006973.

Publisher Copyright:
© 2020 The Author(s)

Keywords

Immune checkpoint blockers
Immunotherapy
Metastatic castration-resistant prostate cancer
PARP inhibitors
PSMA
Prostate cancer
Targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ctarc.2020.100164

Find It

Find It at U of M Libraries

Cite this

@article{e7d6655e192d4d2e838391f89e4269cd,

title = "Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches",

abstract = "Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Immunotherapy, particularly immune checkpoint blockers, PARP inhibitors, and PSMA-targeted therapies are all increasingly being studied for the treatment of mCRPC although none are currently FDA-approved specifically for prostate cancer. Together these three classes of treatments may drastically change the future landscape of mCRPC. This review will cover what is currently known about the utility of these agents for the treatment of mCRPC, the areas of active research, and how these agents may be useful for patients in the future. It will also emphasize the notion of biomarker selection to help inform which patients are more likely to respond to these therapies.",

keywords = "Immune checkpoint blockers, Immunotherapy, Metastatic castration-resistant prostate cancer, PARP inhibitors, PSMA, Prostate cancer, Targeted therapy",

author = "Marshall, {Catherine Handy} and Antonarakis, {Emmanuel S.}",

note = "Funding Information: Disclosures: CHM has received research funding to her institution from the Conquer Cancer Foundation (Bristol Myers Squibb) and travel support from Dava Oncology. She also serves as a paid consultant to McGraw-Hill publishing company. ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck. He has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol-Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Funding: This work was partially supported by National Institute of Health Cancer Center Support Grant P30CA006973. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

doi = "10.1016/j.ctarc.2020.100164",

language = "English (US)",

volume = "23",

journal = "Cancer Treatment and Research Communications",

issn = "2213-0896",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Emerging treatments for metastatic castration-resistant prostate cancer

T2 - Immunotherapy, PARP inhibitors, and PSMA-targeted approaches

AU - Marshall, Catherine Handy

AU - Antonarakis, Emmanuel S.

N1 - Funding Information: Disclosures: CHM has received research funding to her institution from the Conquer Cancer Foundation (Bristol Myers Squibb) and travel support from Dava Oncology. She also serves as a paid consultant to McGraw-Hill publishing company. ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck. He has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol-Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen. Funding: This work was partially supported by National Institute of Health Cancer Center Support Grant P30CA006973. Publisher Copyright: © 2020 The Author(s)

PY - 2020

Y1 - 2020

N2 - Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Immunotherapy, particularly immune checkpoint blockers, PARP inhibitors, and PSMA-targeted therapies are all increasingly being studied for the treatment of mCRPC although none are currently FDA-approved specifically for prostate cancer. Together these three classes of treatments may drastically change the future landscape of mCRPC. This review will cover what is currently known about the utility of these agents for the treatment of mCRPC, the areas of active research, and how these agents may be useful for patients in the future. It will also emphasize the notion of biomarker selection to help inform which patients are more likely to respond to these therapies.

AB - Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Immunotherapy, particularly immune checkpoint blockers, PARP inhibitors, and PSMA-targeted therapies are all increasingly being studied for the treatment of mCRPC although none are currently FDA-approved specifically for prostate cancer. Together these three classes of treatments may drastically change the future landscape of mCRPC. This review will cover what is currently known about the utility of these agents for the treatment of mCRPC, the areas of active research, and how these agents may be useful for patients in the future. It will also emphasize the notion of biomarker selection to help inform which patients are more likely to respond to these therapies.

KW - Immune checkpoint blockers

KW - Immunotherapy

KW - Metastatic castration-resistant prostate cancer

KW - PARP inhibitors

KW - PSMA

KW - Prostate cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85078552123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078552123&partnerID=8YFLogxK

U2 - 10.1016/j.ctarc.2020.100164

DO - 10.1016/j.ctarc.2020.100164

M3 - Article

C2 - 31978677

AN - SCOPUS:85078552123

SN - 2213-0896

VL - 23

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

M1 - 100164

ER -

Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this